Chief Scinetific Officer, OncoQR ML GmbH, Austria
Title: Next generation immuno-therapy: tumour specific control of immune checkpoints
Biography: Geert C. Mudde
Using the S-TIR™ technology platform for human specific therapeutic vaccines OncoQR ML has developed two prototype vaccines for treatment of pancreatic cancer (TYG100) and breast cancer (OQR200). Vaccines derived from this platform consist of 2 modules, the disease specific module, “immunogen” and the generic module, “warhead”, which directs the vaccines to CD32 on antigen presenting cells, especially pDCs and B cells. The immunogen in oncology is a tumour associated auto-antigen, against which under normal conditions no clinically relevant immune responses can be induced. We will present conclusive proof that it is finally possible to overcome all the tricks of cancer cells to prevent therapeutic immune responses. No more need for bulk infusion of very expensive and artificial monoclonal antibodies, which either try to mimic tumour specific B cell responses (e.g. Herceptin and Perjeta) OR try to activate cytotoxic T cells, that by chance may also kill tumours (e.g. Opdivo, Yervoy, Keytruda). S-TIR™ vaccines fully activate both arms of the patient’s own immune system resulting in tumour specific polyclonal IgG responses simultaneously with the generation and activation of tumour specific cytotoxic T cells. The responses are reversible and boostable, thus allowing fine-tuning of the clinical responses on a patient to patient basis. S-TIR™ vaccines in contrast to the current checkpoint inhibitors do not induce autoimmune disease and are tumours specific.